Brain training apps promise measurable cognitive gains from a few minutes of daily gameplay. It's worth separating the marketing from what's actually been shown, and the clearest place to start is a case the government itself pursued.
The Lumosity Case
In 2016, the Federal Trade Commission required Lumosity to pay $2 million to settle charges of deceptive advertising, ruling the company had no scientific backing for claims that its games would help users perform better at work and school, delay age-related cognitive decline, or protect against conditions like Alzheimer's disease.
What the Broader Research Actually Shows
A major research review, Do "Brain-Training" Programs Work? published in Psychological Science in the Public Interest, found a consistent pattern: people reliably get better at the specific games they practice, but that improvement rarely transfers to broader cognitive abilities or real-world tasks the games weren't designed to train.
Why Transfer Is So Hard
Practicing a matching-shapes game makes you better at matching shapes, that's "near transfer," and it's well established. "Far transfer," the improvement actually being marketed, better memory at work, sharper attention in daily life, is the much bigger claim, and it's the part the research consistently fails to support at meaningful levels.
What Has Better Evidence Behind It
The habits with genuinely stronger research behind them aren't flashy: sleep, movement, social connection, and the fundamentals covered in this self-check. None of it is as marketable as a game with a progress bar, but it's what the evidence actually supports.
The Bottom Line
Brain training apps aren't fraudulent in the sense of doing nothing, you do get better at the games themselves. The problem is the gap between that narrow improvement and the broad cognitive benefits actually being sold, a gap large enough that the FTC intervened.
Iso-Alpha delivers a patented, bioavailable blend of isohumulones and xanthohumol designed to activate the gut-brain axis through vagus nerve stimulation. Learn more about the science here.
Written by Ben Vinton
Founder, Iso-Alpha | Brain Health Researcher and Nutraceutical Entrepreneur
Ben Vinton is the founder of Iso-Alpha, a clinically studied brain health supplement built around the gut-brain axis. After watching his grandmother's cognitive decline from Alzheimer's, Ben spent years researching natural, preventive approaches to brain health before developing Iso-Alpha's patented bioavailable formula. He works closely with formulation scientists and practitioners to bring clinical-grade nutraceutical research to everyday consumers.